

Minutes of 2023 Annual General Meeting of Shareholders

Inter Pharma Public Company Limited

Meeting Time & Venue

Inter Pharma Public Company Limited ("the Company") held the 2023 Annual General Meeting of Shareholders on Thursday, April 27, 2023 at 15.00 hrs., via electronic broadcast live (E-Meeting) from the meeting room of Inter Pharma Public Company Limited, 140/9 ITF Tower, 9 Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500

Meeting started at 15.00 hrs.

Clinical Professor Emeritus Dr. Udom Kachintorn, Chairman of the Board of Directors, presided as the Chairman of the meeting thanked the shareholders for attending the 2023 Annual General Meeting of the Company. The Company has deep concern on health and safety of the shareholders and all concerned against the Coronavirus 2019 (COVID-19). The Company has, therefore, arranged the 2023 Annual General Meeting of Shareholders via electronic means (E-Meeting) only. The Chairman opened the meeting and assigned Ms. Chompunuch Meevang, the Company Secretary, as the moderator of the meeting.

The Company Secretary informed the meeting that the 2023 Annual General Meeting of Shareholders will be conducted via electronic means (E-Meeting) only. The Company has complied with the Royal Decree on Electronic Conferencing B.E. 2020 and the Notification of the Ministry of Digital Economy and Society on Security Standards of Electronic Conferencing B.E. 2020. In this meeting the company has assigned Quidlab Co., Ltd., a service provider that has received a certificate for the electronic conferencing control system. According to the information security standard of the Electronic Transactions Development Agency's Conference Control System Register Counting votes in the Annual General Meeting of Shareholders, including organizing the meeting via electronic media system (E-Meeting).

Quorum

At the meeting, 14 shareholders were presence in person, representing 144,318,296 shares, and 27 shareholders by proxy, representing 87,183,769 shares. In total, 41 shareholders, holding a total of 231,502,065 shares, equivalent to 62.1448% of the common shares, which constituted a quorum pursuant to the Company's Articles of Association no. 39 and representing at least one-thirds of shares distributed shall be required.

The Company Secretary introduced to the meeting, the directors, managements, auditors from EY Office Limited and representatives of the auditor being witnesses during the voting process through a video presentation. These persons were as follows:

Directors and Management attending the meeting in person:

1.	Clinical Professor Emeritus Dr. Udom Kachintorn		Chairman of the Board of Directors/ Independent Director/ Chairman of the CG and SD Committee
2.	Prof. Dr. Sansanee	Chaiyaroj*	Independent Director/ Audit Committee/ Chairman of the Risk Management Committee/ CG and SD Committee
3.	Mr. Kamtorn	Sila-on*	Independent Director/ Chairman of the Audit Committee/ Chairman of Nomination and Remuneration Committee / CG and SD Committee
4.	Dr. Pao	Sriprasertsuk*	Independent Director/ Audit Committee/ Nomination and Remuneration Committee/ CG and SD Committee
5.	Dr. Nat	Ativitavas*	Director
6.	Dr. Yutthana	Suwannachot*	Director
7.	Dr. Trinawat	Thanitnithiphan	Director/ Nomination and Remuneration Committee/ Risk Management Committee/ Chairman of Executive Committee and CEO
8.	Ms. Napaporn	Dechakarat	Director/ Risk Management Committee/ Executive Committee and COO
9.	Mrs. Nattarin	Polpueh	Director/ Risk Management Committee/ Executive Committee and CFO
10.	Mrs. Apimon	Posri	Director/ Executive Committee and Human Resource Director

Directors attending the meeting: All 10 persons (equivalent to 100% of the total Board members)

Remarks: **Attended via E-AGM

Management and Others Related:

Mr. Dranan	Jamsai	Executive Committee
Ms. Supaporn	Rerkpitakpanich	Group Accounting & Finance Director
Ms. Chompunuch	Meevang	Company Secretary

Auditors from EY Office Limited:

Ms. Siriwan	Nitdamrong
-------------	------------

Representatives of the Auditor being Witnesses during the Voting Process:

Ms. Jintana	Umpornpa-nga
-------------	--------------

In the meantime, the Company Secretary informed the meeting that the 2023 Annual General Meeting of Shareholders has 13 agenda items as detailed in the invitation letter sent to all shareholders by the Company and has been published on the Company's website. The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during November 1, 2022 - December 31, 2022, in which there were no shareholders proposing agendas and nominate names of persons to be considered for election as a director.

The Company Secretary has clarified the details of the voting method and raising questions can be summarized as follows:

1. In voting of today's meeting, each shareholder has the right to vote which equivalent to the number of shares held. By counting 1 share equal to 1 vote and the shareholders have the right to vote on each agenda to agree, disagree or abstain in just one way or another.
2. In counting the votes, the Company counts the votes of the shareholders who register to attend the meeting via electronic media by pressing one of the voting buttons; agree, disagree or abstain in each agenda at any time when the agenda is not closed. After the agenda is closed, if the shareholders do not press the voting button, the system will consider that the shareholders is agreed and cannot change the voting.
3. In addition, for the proxies whose voters have already specified their voting for each agenda item in the proxy form, the Company has counted your votes from the proxy form. This is for the convenience of shareholders.
4. For reading the voting results in each agenda, the Chairman and or the Company Secretary will inform the meeting of the voting results of each agenda. The results of the votes will be the votes that include the votes of the shareholders who attend the meeting, both in person and by proxy. Each agenda will use the number of shares of the latest attendees in that agenda.
5. In each agenda, there will be an opportunity for shareholders to ask questions by sending questions through typing in texts or sending voice messages. In doing so, the shareholders have to click on the Question Menu, type your message in the text box. If shareholders have experienced any problems during the electronic meeting, please contact Quidlab Company Limited at 02-013-4322 or email: info@quidlab.com.

In this regard, The Company reserves the right to consider and select questions as appropriate in case of a large number of questions being sent into the system, if there are any questions that cannot be answered during the meeting due to limited time. The Company will consider collecting, answering and disclosing in the minutes of the shareholders' meeting. which the company will disseminate through the information system of the Stock Exchange of Thailand and on the Company's website within 14 days from the date of the shareholders' meeting.

When shareholders are aware and have no other opinion on the voting method and asking questions as presented above, the Chairman shall proceed the meeting according to the agenda as follows:

Agenda 1 To certify the Minutes of the Extraordinary General Meeting of Shareholders No. 1/2022

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company prepares the minutes of the Extraordinary General Meeting of Shareholders No. 1/2022 on July 20, 2022, The Board of Directors has considered the minutes had been duly and accurately recorded and reflected the resolutions passed by the said Shareholders' Meeting, the copies of which had been sent to the shareholders together with the notice of this Meeting as per Attachment No. 1.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to consider approving the Minutes of the Extraordinary General Meeting of Shareholders No. 1/2022.

Meeting Resolution The meeting considered and unanimously resolved to certify the Minutes of the Extraordinary General Meeting of Shareholders No. 1/2022 with the following votes:

Agree	231,647,065	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.00
Abstain	0	votes	% equivalent to	0.00

Remark: On this agenda, there was an additional 145,000 shares attending the Meeting, resulting in the total number of shareholders attending the Meeting a total of 231,647,065 shares.

Agenda 2 To acknowledge the Company's performance for the year 2022 and approve the annual financial statements ended December 31, 2022

The Chairman assigned Mrs. Nattarin Polpueh, Director and Chief Finance Officer, to inform the Meeting of the details regarding this agenda

Mrs. Nattarin Polpueh, Director and Chief Finance Officer informed the Meeting that the Company's performance for the year 2022 is as follows:

The Company has total revenue from sales and services 1,523 million baht, increased by 615 million baht or 67.7% YoY. These was contributed by Human healthcare segment +103.6%, driven by growth from pharmaceutical products, combining the pharmacy and hospital businesses and revenue from animal healthcare segment was 6.5% growth driven by companion animal healthcare.

Revenue by segment as follows;

1. Revenue of Pharmaceutical Products accounted for 380 million baht, increased by 74.5%, represented as 25.0% of revenue from sales, contributed by growth of Pharmaceutical Products of Ayutthaya Plant and Modern Pharma. The key products were diabetes medicine

(Meforin) Dyslipidemia Agent (Zimmex) Anti-Viral (Virogon) Anti-Allergic (Zensil) Analgesic Antipyretics) (Pyrana) mucolytic (Supenac).

2. Revenue from Wellness & Cosmeceuticals was 355 million baht, represented as 23.3% of revenue from sales, slightly increased 0.2% YoY. The revenue from Wellness & Anti-Aging Nutraceuticals continued growing, driven by Probac 7, Probac Ultra Collagen, TS6 Probiotics, Probac 10 Plus, Probac Mood, PreBO.
3. Product for Companion Animal Healthcare continued growing, driven by pet food under the brand MARIA and CHOO CHOO, nutraceuticals for pets (Dr.Choice, Pet Select) and pharmaceutical for pets (MOXCLAVET, FENAMAX TABLET, ENROPHAR)
4. Product for Livestock animal healthcare dropped from poultry meal and porcine meal, due to natural disaster and pig plague. These impacted to lower demand of raw material and pharmaceutical products.
5. Revenue from Pharmacy stores was 401 million baht, represented as 26.3% of revenue from sales. Currently, there are 21 branches and 1 online platform.
6. Revenue from Hospital was 29 million baht, including 1.5 months of operations.

The Company and its Subsidiaries had a net profit 131 million baht, an increase of 21 million baht or 18.9% YoY, representing a revenue-to-income ratio of 8.6 percent, a decrease compared to the same period last year. The major reasons were lower gross profit margin from higher revenue proportion of Pharmaceutical Products, Lab Pharmacy and Hospital, which has a lower gross profit margin than the previous business and increased sales and administrative expenses from expanding the sales team, marketing team, IT expenses, and consulting fees for investing in new businesses.

Chief Finance Officer informed the Meeting that the Company has prepared the Financial Statements for the year ended December 31, 2022, as duly audited and certified by the auditor from EY Office Limited and reviewed by the Audit Committee. The summary of the Company's financial status and performance during the year 2022 is as follows:

		Consolidated Financial Statement		Separate Financial Statement	
		2022	2021	2022	2021
Total Assets	(Million Baht)	3,025.82	1,327.04	2,380.83	1,139.29
Total Liabilities	(Million Baht)	952.25	543.54	458.87	361.48
Total Revenue	(Million Baht)	1,534.45	920.98	623.24	619.18
Profit (Loss) for the year*	(Million Baht)	119.24	105.22	101.66	125.46
Earning (Loss) per share	(Baht :Share)	0.364	0.360	0.311	0.429

*Profit for the year: Equity Holders of the Company

The Company Secretary inform that the Company is highly emphasize on anti- corruption. The Company has created an anti-corruption policy to serve as a guideline for the conduct of directors, executives, and employees of the Company. which must be strictly adhered to. If there are any clues about corruption or complaints related to the Company's business can be notified via email: comsec@interpharma.co.th or deliver by post to the Company's address. In the past, the Company has not found any complaints related to corruption or related to the Company's business. And the Company is currently studying guidelines for joining the Thai Private Sector Collective Action Coalition Against Corruption (CAC). If there is progress, we will inform shareholders in the future.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions:

1. Mr. Apichart Preetimakorn, a shareholder, inquired that the Company has income in each quarter of the past year has grown significantly, but SG&A expenses grew more than revenue. How will the management solve this problem?

Chief Executive Officer answered the question that the business that the Company invests in the beginning, there will be expenses for improving and developing the business. To be in line with the Company's future vision, such as investing in the drugstore business. The Company plans to improve in several areas, improving the Customer Relationship Management or CRM system, which will support branch expansion plans. and future business expansion and most importantly, personnel must be recruited, including pharmacists, who are important employees of pharmacies. which must be recruited in advance. At present, the Company's drugstores are rapidly expanding from 20 branches to now 24 branches. According to the Company's plan for 2023, 15 more branches will be opened, bringing the total to 35 branches. The Company views this investment as a famous investment. It is said to be a long-term investment. The factory previously purchased by the Company is in the process of being renovated and developed. There has been a shift to using an Enterprise Resource Planning or ERP system, which has led to increased costs. In terms of sales and marketing, there will be expenses for branding. which from a marketing perspective is seen as a long-term asset but from an accounting point of view, the expenses incurred cannot be averaged. It is considered an expense in the cycle that occurs. The Company expects that after improving the brand, the business will grow.

2. Mr. Sakol Sukwanichwchai, a proxy from the Thai Investors Association, inquired that (1) The Company plans to reach new target customer groups, such as healthcare groups and more advanced technology user by the way, is it mainly online marketing and social media? (2) There are probiotic supplement products that are showing interesting growth rates, such as supplements that contain ingredients from cannabis herbs, kratom, iron minerals, etc. How does the Company plan to develop these products further?

Chief Executive Officer answered the question that the Company already has plans to reach new customer groups through social media channels. The company will not focus heavily on cannabis because it is still quite an issue and in kratom section, the company is waiting for regulations from the Food and Drug Administration ("FDA"). The Company has developed kratom products in the form of healthy herbs. and health

drinks are already waiting for the FDA to approve registration, the Company's coordination with the FDA, it is expected to be able to register within 1-2 months.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to acknowledge the Company's performance for the year 2022 and approve the annual financial statements ended December 31, 2022.

Meeting Resolution The meeting considered and resolved to acknowledge the Company's performance for the year 2022 and agreement the annual financial statements ended December 31, 2022 as proposed with the following votes:

Agree	231,647,265	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.00
Abstain	1	votes	% equivalent to	0.00

Remark: On this agenda, there was an additional 200 shares attending the Meeting, resulting in the total number of shareholders attending the Meeting a total of 231,647,265 shares.

Agenda 3 To consider and approve the allocation as a legal reserve and the dividend payment for operating results of the year 2022

The Chairman assigned Ms. Chompunuch Meevang, Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 115 of the Public Limited Company Act and Article 51 of the Company's Articles of Association, provide that no dividends shall be paid other than out of profits. The Company's policy is to pay dividends at the rate of not less than 50 percent of the net profits after deducting the legal reserves and, provided that dividend payment will be subjected to the Company's cash flow, investment plan, conditions and terms of agreements to which the Company is bound, as well as the necessity and other appropriateness in the future.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the annual dividend payment for the operating results of the year 2022 at 0.18 Baht per share to 372,520,524 shares, totaling approximately 67.05 Million Baht or approximately 69.44 % of the net profit after deductions of all categories of reserves as specified in the Company's Articles of Association and applicable laws, which is in accordance with the Company's dividend payment policy.

The Board of Directors has set the Record Date on May 9, 2023 to determine the name of shareholders who are entitled to receive the dividend and to pay the dividend on May 26, 2023.

The comparison of dividend payments during the past 3 years is detailed as follows:

Description	2022 (proposed year)	2021	2020
Dividend Payment (Million Baht)	67.05	-	46.02
● Dividend for year (Baht : share)	0.18	-	0.2234
○ Stock Dividend Payout Ratio (Existing Share : Stock Dividend)	-	-	2.50 : 1
○ Stock Dividend Payout Ratio (Baht : Share)	-	-	0.20
○ Cash Dividend Payout Ratio (Baht : Share)	0.18	-	0.0234
Dividend Payment to Net Profit Ratio (%)	69.44	-	89.99

And according to Section 116 of the Public Limited Company Act and Clause 53 of the Company's Articles of Association, the Company must allocate part of the annual net profit as reserve fund in an amount not less than five percent of the annual net profit less the sum of accumulated loss brought forward (if any) until the reserve fund amounts to be not less than ten percent of the registered capital.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the allocation of net profit for the year 2022 in the amount of 5.09 Million Baht

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to consider and approve the allocation of 2022 as a legal reserve and the dividend payment for operating results of the year 2022.

Meeting Resolution The meeting considered and agreement the allocation of 2022 as a legal reserve and the omitted dividend payment for operating results of the year 2022 with the following:

Agree	231,647,365	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.00
Abstain	0	votes	% equivalent to	0.00

Remark: On this agenda, there was an additional 100 shares attending the Meeting, resulting in the total number of shareholders attending the Meeting a total of 231,647,365 shares.

Agenda 4 To consider and approve the issuance and offering of warrants to purchase the Company's ordinary shares No. 2 (IP-W2)

The Chairman assigned Ms. Chompunuch Meevang, Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to the Company has the issuance and offering of warrants to purchase ordinary shares of Inter Pharma Public Company Limited No. 2 ("Warrant No. 2" or "IP-W2") in the amount of 93,130,131 units, which will be allocated to existing shareholders in proportion to their shareholding at the ratio of 4 existing ordinary shares per 1 unit of Warrant. The Company's objective is to use the proceeds from the IP-W2 exercise for investment in expanding its business, debt repayment and as the working capital of the Company (Attachment No. 4).

In addition, the Board of Directors will determine the date for determining the names of shareholders who are entitled to be allocated Warrant No. 2 (Record Date) on May 9, 2023, and has authorized the Board of Directors to consider cancelling or setting an alternative Record Date as appropriate, taking into account the benefits and impacts on the Company. However, the allocation of Warrant No. 2 is still uncertain, pending approval by the Annual General Meeting of Shareholders.

Additionally, the Board of Directors and/or authorized directors of the Company, or persons assigned by the Board of Directors or the authorized directors of the Company, are authorized to

(1) determine and amend the necessary and appropriate conditions and other details in connection with the issuance of Warrants, such as offering details;

(2) sign various permission application documents and necessary evidence related to the issuance of Warrants, including submitting an application for approval of such documents and evidence to government agencies or agencies related to the issuance and listing of the Warrants on the Market for Alternative Investment (MAI); and

(3) take action as necessary and appropriate in connection with the issuance of the Warrants at this time.

Further details regarding the summary of Preliminary Details of the Warrants to Purchase Ordinary Shares of Inter Pharma Public Company Limited No. 2 (IP-W2) (Attachment No. 4).

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to consider and approve the issuance and offering of warrants to purchase the Company's ordinary shares No. 2 (IP-W2)

Meeting Resolution The meeting considered and agreement the issuance and offering of warrants to purchase the Company's ordinary shares No. 2 (IP-W2) with not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote as follow:

Agree	200,497,629	votes	% equivalent to 82.5530
Disagree	31,034,936	votes	% equivalent to 13.3975
Abstain	114,800	votes	% equivalent to 0.0496

Agenda 5 To consider and approve the capital decrease of the Company's registered capital by means of canceling the unissued registered shares of the Company and the amendment to Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the meeting that according to Section 136 of Public Limited Companies Act, B.E. 2535 (1992) (as amended), the Company may issue new shares when all shares have been sold and fully paid-up, except for the remaining shares which are issued for the exercise of warrants reserved for the exercise of the warrant to subscribe for the shares.

At present the Company has a registered capital of 216,218,625.50 Baht divided into 432,437,251 shares with a par value of 0.50 Baht per share, and paid-up capital of 186,260,262 Baht divided into 372,520,524 shares with a par value of 0.50 Baht per share,

The Company has the unissued registered shares of the Company in the amount 59,916,727 shares, which consists:

- (1) Reserve for the exercise of the warrants to purchase the Company's ordinary shares No. 1 (IP-W1) of 19,221,866 shares
- (2) Reserve for the adjustment of the warrants to purchase the Company's ordinary shares No. 1 (IP-W1) of 1,854,902 shares
- (3) Reserve for the capital increase under the General Mandate of 38,839,959 shares

The Company shall reduce its registered capital of 19,419,979.50 Baht from the registered capital of 216,218,625.50 Baht to 196,798,646 Baht by canceling 38,839,959 shares unpaid-up ordinary shares with a par value of 0.50 Baht per share, which is the remaining ordinary shares reserved for the capital increase under General Mandate and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital as follows;

“Article 4. Registered capital	196,798,646	Baht	(One hundred ninety-six million seven hundred ninety-eight thousand six hundred forty-six Baht)
Divided into	393,597,292	shares	(Three hundred ninety-three million five hundred ninety-seven thousand two hundred ninety-two shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			

Ordinary shares	393,597,292	shares	(Three hundred ninety-three million five hundred ninety-seven thousand two hundred ninety-two shares))
Preferred shares	- None –	-”	

In addition, the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to consider and approve the capital decrease of the Company's registered capital by means of canceling the unissued registered shares of the Company and the amendment to Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital.

Meeting Resolution The meeting considered and agreement the approve the capital decrease of the Company's registered capital by means of canceling the unissued registered shares of the Company and the amendment to Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's with not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote as follow:

Agree	231,647,365	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.00
Abstain	0	votes	% equivalent to	0.00

Agenda 6 To consider and approve the capital increase of the Company's registered capital and the amendment to Article 4 of the Company's Memorandum of Association to comply with the increase of the Company's registered capital

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Company would like to approve the capital increase of the Company of 46,565,065.50 Baht from the former registered capital of 196,798,646 Baht to 243,363,711.50 Baht by issuing 93,130,131 newly issued ordinary shares with a par value of 0.50 Baht per share to allocate reserve for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) and the amendment of the Memorandum of Association Article 4 of the Company's Memorandum of Association to comply with the increase of the Company's registered capital as follows;

“Article 4. Registered capital	243,363,711.50	Baht	(Two hundred forty-three million three hundred sixty-three thousand seven hundred eleven Baht fifty Satang.)
Divided into	486,727,423	shares	(Four hundred eighty-six million seven hundred twenty-seven thousand four hundred twenty-three shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			
Ordinary shares	486,727,423	shares	(Four hundred eighty-six million seven hundred twenty-seven thousand four hundred twenty-three shares)
Preferred shares	- None –	-”	

In addition, the authorization to the authorized directors of the Company in accordance with the Company’s affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item. The Chairman proposed the meeting to consider and approve the capital increase of the Company’s registered capital and the amendment to Article 4 of the Company’s Memorandum of Association to comply with the increase of the Company’s registered capital.

Meeting Resolution The meeting considered and agreement the capital increase of the Company’s registered capital and the amendment to Article 4 of the Company’s Memorandum of Association with not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote as follow:

Agree	228,709,965	votes	% equivalent to	98.7320
Disagree	2,937,400	votes	% equivalent to	1.2680
Abstain	0	votes	% equivalent to	0.00

Agenda 7 To consider and approve the allocation of newly issued ordinary shares of the Company

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the capital increase plan in Agenda 6 above, the Company will allocate not more than 93,130,131 newly issued ordinary shares at a par value of 0.50 Baht per share, to accommodate the exercise of Warrants to purchase ordinary shares of the Company No. 2

(IP-W2). The Warrants will be allocated to existing shareholders of the Company in the ratio of 4 existing ordinary shares per 1 unit of Warrants, with an exercise price of 20 baht per share. (Attachment No. 4).

The Company will assign the Board of Directors and/or Chief Executive Officer and/or persons assigned by the Board of Directors and/or Chief Executive Officer are authorized to determine and amend the conditions and details related to the issuance and allocation of the newly issued ordinary shares, including but not limited to:

(1) Changes to the conditions and other details related to the adjustment or change of the exercise ratio and exercise price, in accordance with the terms and conditions.

(2) Entering into negotiations, make agreements, and sign relevant documents and contracts, as well as take any necessary and appropriate actions related to the allocation of the newly issued ordinary shares.

(3) Sign the application for permission, waiver, and evidence necessary and related to the issuance and offering of such newly issued ordinary shares, including but not limited to providing information and submitting documents and evidence to the Securities and Exchange Commission, the Stock Exchange of Thailand, Thailand Securities Depository Co., Ltd., Ministry of Commerce, or other related agencies. They are also authorized to take any other actions necessary and relevant to the issuance and offering of such newly issued ordinary shares, including listing them as securities on the Market for Alternative Investment (MAI).

(4) Take necessary action to reassemble and distribute the newly issued ordinary shares.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Company Secretary proposed to the meeting to consider and approve the allocation of newly issued ordinary shares of the Company

Meeting Resolution The meeting considered and agreement the approve the allocation of newly issued ordinary with the following votes:

Agree	208,595,165	votes	% equivalent to	90.0486
Disagree	23,052,200	votes	% equivalent to	9.9514
Abstain	0	votes	% equivalent to	0.00

Agenda 8 To consider and approve the appointment of directors replacing those due to retire by rotation

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Section 71 of the Public Limited Company Act and Clause 21 of the Company's Articles of Association, stipulates that in every annual general meeting of shareholders one third (1/3) of the total number of Directors shall vacate office. If the number of Directors

vacating office cannot be exactly divided by one-third (1/3), the number that is similar to one-third (1/3) shall be used. However, Directors who due to retire can be re-elected to return to the position again.

The 2023 Annual General Meeting of Shareholders, there are 4 directors who have completed their term of office as follows:

- | | |
|---|---|
| 1. Clinical Professor Emeritus Udom Kachintorn, MD. | Chairman and Independent Director |
| 2. Dr. Pao Sriprasertsuk | Independent Director and Member of
the Audit Committee |
| 3. Dr. Trinnawat Thanitnithiphan | Director |
| 4. Ms. Napaporn Dechakarat | Director |

The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during November 1, 2022 – December 31, 2022, in which there were no shareholders proposing agendas and names of persons to be considered for election as a director.

The Nomination and Remuneration Committee (excluding the stakeholders) has carefully reviewed before presenting to the Board of Directors and to propose to the Annual General Meeting of Shareholders for election directors, considering the qualifications of directors as specified in the relevant laws, the Company's regulations, proportion and qualification of Independent Directors according to the definition of Independent Director of the Company, as well as knowledge, capabilities and experience that are useful to the Company's business. The Nomination and Remuneration Committee deemed it appropriate to propose the appointment of Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Pao Sriprasertsuk, Dr. Trinnawat Thanitnithiphan and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Nomination and Remuneration Committee considered that all candidates nominated have all qualifications as specified by relevant regulations and suitable for the business, and the candidates nominated as independent directors are fully qualified in accordance with the law and regulations relating to independent directors and are able to provide opinions independently.

The Board of Directors (excluding stakeholders) considered the list of nominated persons, which have been carefully screened and considered by the Nomination and Remuneration Committee, and deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint 4 directors, namely Clinical Professor Emeritus Udom Kachintorn, MD., Dr. Pao Sriprasertsuk, Dr. Trinnawat Thanitnithiphan and Ms. Napaporn Dechakarat to return to serve as Directors for another term. The Board of Directors considered that the candidates nominated as an Independent Directors have all qualifications as specified by relevant regulations and are able to provide opinions independently. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation in Attachment No.5.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda.

The Company Secretary informed of the voting procedures for the election of directors, as detailed below.

Clause 19 of the Company's Articles of Association stipulates the director voting procedures as follows:

- (1) A shareholder shall have one vote for each share he holds or represents.
- (2) The shareholders shall vote for each individual candidate nominated for directors, but not exceeding the number of directors required for that election. The vote shall not be distributed.
- (3) The candidates shall be ranked in order descending from the highest number of votes received to the lowest, and shall be appointed as directors in that order until all of the director positions are filled. Where the votes cast for candidates in descending order are tied, which would otherwise cause the number of directors to be exceeded, the remaining appointment shall be made by the Chairman of the Meeting who shall have a casting vote.

For Agenda 8, the Meeting was requested to consider the candidates on an individual basis in the order as appeared in Agenda 8 of the Notice of the meeting, which showed the list of all nominated candidates.

The Company Secretary then proposed that the shareholders vote on the candidates on an individual basis, whereby this year there were four candidates nominated for election as directors to replace the directors due to retire by rotation, equivalent to the number of directors

Meeting Resolution The meeting considered and agreement the appointment of directors replacing those due to retire by rotation with the following votes:

- | | |
|--|--|
| (1) Clinical Professor Emeritus Udom Kachintorn, MD. | Chairman of the Board of Directors / |
| | Independent Director |
| Agree | 231,647,365 votes % equivalent to 100.00 |
| Disagree | 0 votes % equivalent to 0.00 |
| Abstain | 0 votes % equivalent to 0.00 |
| (2) Dr. Pao Sriprasertsuk | Independent Director |
| Agree | 231,647,365 votes % equivalent to 100.00 |
| Disagree | 0 votes % equivalent to 0.00 |
| Abstain | 0 votes % equivalent to 0.00 |
| (3) Dr. Trinawat Thanitnithiphan | Director |
| Agree | 231,647,365 votes % equivalent to 100.00 |
| Disagree | 0 votes % equivalent to 0.00 |
| Abstain | 0 votes % equivalent to 0.00 |

(4) Ms. Napaporn Dechakarat		Director		
Agree	200,612,429	votes	% equivalent to	86.6025
Disagree	31,034,936	votes	% equivalent to	13.3975
Abstain	0	votes	% equivalent to	0.0000

Agenda 9 To consider and approve the remuneration of directors for the year 2023

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Article 26 of the Company's Articles of Association, Directors are eligible for remuneration in forms of rewards, meeting allowance, gratuity, bonus or other benefit according to the resolution of the Shareholders' Meeting by not less than two-thirds (2/3) of the total number of vote of the shareholders attending the meeting and having the right to vote.

The Nomination and Remuneration Committee conducted a survey on remuneration for the Board of Directors and sub-committees for the year 2023, considering the suitability from the scope of duties and responsibilities, the responsibilities and performance of the Board of Directors and each sub-committee, business expansion, the Company's performance and comparative information with other companies in the same industry with similar size and nature of the business and considered appropriate to maintain the remuneration of the Board of Directors and sub-committees, including monthly remuneration and meeting allowance at the same rate as year 2022 and increase the total remuneration from 3 Million Baht to 4 Million Baht due to the increase in the number of non-executive directors and the Company has continued to expand its business as a result, the Company may have to hold more meetings of the Board of Directors and sub-committees than last year.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the remuneration of the Board of Directors and sub-committees for the year 2023 (proposed year) at the same rate as year 2022 as proposed by the Nomination and Remuneration Committee who had taken into consideration various factors and criteria as follows:

Position	2023 (proposed year)	2022
Monthly remuneration (person : month)		
For non-executive directors		
● Chairman	30,000 Baht	30,000 Baht
● Director	20,000 Baht	20,000 Baht
Meeting Allowance		
For non-executive director (Baht : time) (pay only to meeting attendee)		

Position	2023 (proposed year)	2022
<u>Board of Directors</u>		
● Chairman	20,000 Baht	20,000 Baht
● Director	15,000 Baht	15,000 Baht
<u>Audit Committee</u>		
● Chairman	22,500 Baht	22,500 Baht
● Director	15,000 Baht	15,000 Baht
<u>Nomination and Remuneration Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Corporate Governance and Sustainable Development Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Risk Management Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht

For the policy of paying bonuses to independent directors and non-executive directors (whole board), the Company pays no more than 0.5% of the announced dividend amount. The monthly remuneration, meeting allowance and other benefits, the total amount must not exceed 4 Million Baht. By assigning the Board of Directors or the person assigned by the Board of Directors to consider and allocate bonuses to independent directors and non-executive directors.

The 2022, the total remuneration and bonus of the Board of Directors and sub-committees was approximately 2.37 Million Baht, not exceeding the rate approved by the above meeting of shareholders. Details are as shown in the Annual Report 2022 (Form 56-1 One Report) in page 135

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Company Secretary proposed to the meeting to consider and approve the remuneration of directors for the year 2023

Meeting Resolution The meeting considered and agreement the remuneration of directors for the year 2023 with a vote of not less than two-thirds of the total number of votes of the shareholders who attend the meeting and have the right to vote as follow:

Agree	230,456,956	votes	% equivalent to	99.4861
Disagree	1,190,400	votes	% equivalent to	0.5139
Abstain	0	votes	% equivalent to	0.0000

Agenda 10 To consider and approve the appointment auditors and audit fee for the year 2023

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 120 of the Public Company Limited Act B.E. 2535 (1992) (as amended), which stipulates that the Annual General Meeting of Shareholders shall appoint auditors and determine audit fees every year. In appointing the auditor, the same auditor may be reappointed.

The Audit Committee has considered and approved the selection of auditors from EY Office Limited to be the auditors of the Company and its subsidiaries for the year 2023, which has been the same auditor for the third consecutive year. EY Office Limited has satisfactorily performed its duties to the Company in accordance with the auditing standards and provided useful opinions useful opinions to the Company and independent and agreed that the audit fee proposed by EY Office Limited was appropriate, when compared to the scope of service and workload.

With careful consideration Audit Committee, The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint auditors from EY Office Limited, which is the same auditor as the Company's subsidiaries, whereby one of the following auditors will be appointed as the auditor of the Company for the year 2023.

- | | |
|----------------------------------|---|
| 1. Ms. Siriwan Nitdamrong, | Certified Public Accountant No. 5906 and / or |
| 2. Ms. Kamonthip Lertwitworathep | Certified Public Accountant No. 4377 and / or |
| 3. Ms. Satida Rattananurak | Certified Public Accountant No. 4753 and / or |
| 4. Mrs. Sarinda Hirunprasertwut | Certified Public Accountant No. 4799 |

Ms. Siriwan Nitdamrong, Certified Public Accountant No. 5906, who has signed the company's financial statements since the 1st quarter of 2021 until the 2022 annual financial statements. All above four auditors are qualified and has no relationship or any conflict of interest with the Company, its subsidiaries and associates, management, major shareholders or any person related to such person. Therefore, there is independence in auditing and express an opinion on the Company's financial statements, its subsidiaries and associates including the certified auditors as above, no auditors have performed the audit duties of the Company for more than the period specified in the relevant announcement. (Profiles of the Auditors proposed for the year 2023, **Attachment No. 6**)

The Board of Directors also deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the audit fees of the Company for the year 2023 (not include non-audit fee) as follows:

List of services	2023 (proposed year)	2022	Increase/(Decrease)
Audit fee of the Company	1,790,000	1,600,000	190,000

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Company Secretary proposed to the meeting to consider and approve the appointment auditors and audit fee for the year 2023

Meeting Resolution The meeting considered and agreement the appointment auditors and audit fee for the year 2023 with the following votes:

Agree	231,532,565	votes	% equivalent to	99.9504
Disagree	114,800	votes	% equivalent to	0.0496
Abstain	0	votes	% equivalent to	0.0000

Agenda 11: To consider and approve the amendment to the Company's Articles of Association

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that Due to the enactment of the Public Limited Companies Act, B.E. 2535 (1992) (No. 4) in 2022, state that public limited companies can use electronic methods in their Board of Directors meetings and shareholders' meetings, serving notices or documents, and granting proxies for shareholders' attendance to support the developments and changes in technology. Therefore, the Company should amend its Articles of Association to comply with such provisions.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the amending a total of 6 clauses in the Company's Articles of Association, namely Article 29, Article 35, Article 38, Article 39, Article 51, and Article 57. In order to be consistent with the Public Limited Companies Act B.E. 2535 ("Public Limited Companies Act"), which has been amended in 2022, it is proposed to cancel the old text and use the following new text instead.

Existing Articles of Association	New Articles of Association
Article 29. Regarding the convening of a meeting of the Board of Directors, whether in person or through electronic means, the Chairman of the Board or a person assigned by him shall send the meeting notice to the Directors at least seven (7) days prior to the meeting date, except in cases of urgent necessity to protect the rights and benefits of the Company. In such cases, the meeting notice may be sent by other methods and the meeting date shall be set accordingly. If it is a meeting of the Board of Directors	Article 29. In convening a meeting of the Board of Directors, whether in person or through electronic meetings, the Chairman of the Board or a person assigned by him shall send the meeting notice to the Directors at least <i>three (3)</i> days prior to the meeting date, except in cases of urgent necessity to protect the rights and benefits of the Company. In such cases, the meeting notice may be sent by <i>electronic means or any other means</i> and the meeting date shall be set

Existing Articles of Association	New Articles of Association
<p>held via electronic means, the meeting invitations and documents can be sent by electronic mail. son or through electronic meetings. The chairman of the board or a person assigned by him shall send the meeting notice to the directors at least seven (7) days prior to the meeting date. Except in case of urgent necessity to protect the rights and benefits of the Company. will notify the meeting by other methods and set the meeting date If it is a meeting of the Board of Directors via electronic means Sending meeting invitations and meeting documents can be sent by electronic mail</p>	<p>accordingly. If it is a meeting of the Board of Directors held via electronic means, the meeting invitations and documents can be sent by electronic mail.</p> <p><i><u>In summoning a meeting of the Board of Directors under paragraph one, if there is no Chairman or person assigned for whatever reason, the Vice-Chairman shall be responsible for calling the meeting of the Board of Directors. In the absence of the Vice-Chairman for whatever reason, two (2) or more Directors may jointly call a meeting of the Board of Directors.</u></i></p> <p><i><u>If there is a reasonable cause or to protect the rights or benefits of the company, two (2) or more Directors may jointly request that the Chairman of the Board or the person assigned call a meeting of the Board of Directors, provided that the subjects and reasons to be proposed for consideration are also specified. In such a case, the Chairman or the person assigned by him shall call and schedule the meeting within fourteen (14) days from the date of receiving the request.</u></i></p> <p><i><u>If the Chairman or his entrusted person fails to comply with paragraph three, the requesting Directors may jointly call and schedule a meeting of the Board of Directors to consider the requested matter within fourteen (14) days from the expiration of the period under paragraph three.</u></i></p>

Existing Articles of Association	New Articles of Association
<p>Article 35. The Board of Directors must meet at least once every three (3) months at the location of the Company's head office or nearby provinces, or at any other place as determined by the discretion of the Chairman of the Board. The date, time, and place of the meeting shall be determined by the Chairman of the Board.</p>	<p>Article 35. The Board of Directors must meet at least <u>one (1)</u> time every three (3) months at the location of the Company's head office or nearby provinces. <u>If the meeting is held via electronic media in accordance with the Royal Decree on Electronic Conferencing, the Company's head office shall be deemed to be the venue of the meeting.</u></p>
<p>Article 38. In calling a shareholders' meeting, the Board of Directors shall prepare a written notice of the meeting, which specifies the place, date, time, and agenda of the meeting, as well as the matters to be proposed with appropriate details. The notice shall clearly state whether the matter will be proposed for acknowledgment, approval, or consideration, as the case may be, including the opinion of the Board of Directors on such matter. The notice shall be delivered to shareholders and the registrar not less than seven (7) days prior to the date of the meeting and shall be published in a newspaper as required by law, before the date of the meeting.</p> <p>The meeting shall be held at a location within the province where the Company's head office is located or at nearby provinces, as may be determined by the Board of Directors.</p>	<p>Article 38. The Board of Directors shall prepare a written notice of the meeting, which specifies the place, date, time, and agenda of the meeting, as well as the matters to be proposed with appropriate details. The notice shall clearly state whether the matter is proposed for acknowledgment, approval, or consideration, as the case may be, and include the opinion of the Board of Directors on the matter. The notice shall be sent to the shareholders and the Registrar at least seven (7) days prior to the meeting date, and published in a newspaper prior to the meeting date, as required by law. <u>Alternatively, electronic media may be used in accordance with the rules and procedures prescribed by law.</u></p> <p>However, the place to be used as the <u>meeting place must</u> be in the area where the company's head office is located or nearby provinces, <u>or anywhere else</u> as may be determined by the Board. <u>If a meeting is held via electronic means, it shall be deemed that the Company's head office is the</u></p>

Existing Articles of Association	New Articles of Association
	<p><i>venue of the meeting, and such meeting shall have the same effect as a meeting of shareholders attending the same meeting in person in accordance with the rules and procedures prescribed by law.</i></p>
<p>Article 39. In the shareholders' meeting, there must be at least twenty-five (25) shareholders and proxies (if any) attending the meeting or not less than half (1/2) of the total number of shareholders, whichever is less, and they must hold shares amounting to not less than one-third (1/3) of the total number of shares sold, thus forming a quorum.</p> <p>If a shareholders' meeting fails to have a quorum as specified in the first paragraph, meaning there are not enough shareholders in attendance after one (1) hour from the appointed time, the actions taken depend on whether the meeting was called at the request of shareholders or not. If the meeting was called at the request of shareholders, the meeting is suspended. If the meeting was not called at the request of shareholders, a new meeting is scheduled, and notice of the meeting must be sent to the shareholders not less than seven (7) days prior to the meeting date. In the later meeting, a quorum is not required.</p> <p>Each shareholder may appoint one proxy to attend and vote at the meeting on his/her behalf. The form of proxy must be in the form set by the registrar, and must be delivered to the Chairman of the Board or the person designated by the Chairman at</p>	<p>Article 39. In the shareholders' meeting, <i>whether meeting in person or via electronic media</i>, there must be at least twenty-five (25) shareholders and proxies (if any) attending the meeting or not less than half (1/2) of the total number of shareholders, and they must hold shares amounting to not less than one-third (1/3) of the total number of shares sold, thus forming a quorum.</p> <p>If a shareholders' meeting fails to have a quorum as specified in the first paragraph, meaning there are not enough shareholders in attendance after one (1) hour from the appointed time, the actions taken depend on whether the meeting was called at the request of shareholders or not. If the meeting was called at the request of shareholders, the meeting is suspended. If the meeting was not called at the request of shareholders, a new meeting is scheduled, and notice of the meeting must be sent to the shareholders not less than seven (7) days prior to the meeting date. In the later meeting, a quorum is not required.</p> <p>Each shareholder may make not more than one proxy form to attend and vote on his/her behalf in the form prescribed</p>

Existing Articles of Association	New Articles of Association
<p>the meeting place before the meeting.</p> <p>Proxies can attend the meeting and only one person may act as a proxy, regardless of whether the proxy holds more or less of the company's shares.</p>	<p>by the Registrar, and delivered to the Chairman of the Board or the person designated by the Chairman at the meeting place before the proxy attends the meeting. <i>Or the proxy may be made by electronic means instead. It must use a method that is safe and reliable that the proxy is made by the shareholder and in accordance with the criteria prescribed by the Registrar.</i></p> <p>The proxy for such purpose may only be one person, regardless of the number of shares held by the shareholder.</p>
<p>Article 51. Dividends shall only be distributed from profits. When the Company's proceeds are at a loss, dividends shall not be distributed.</p> <p>Dividends shall be divided equally according to the number of shares, except in the case where the Company issues preferred shares and requires that preferred shares receive dividends different from ordinary shares. To allocate dividends as specified. The dividend payment must be approved by the shareholders' meeting.</p> <p>The interim dividend may be paid from time to time when the Company has reasonable profits to do so and shall report it to the next shareholders' meeting.</p> <p>Dividend distribution shall be done within one (1) month from the date of the shareholders' meeting or in accordance with the Board of Directors' consensus. A notification and written announcement shall be made to shareholders for at least three (3) consecutive days.</p>	<p>Article 51. Dividends shall only be distributed from profits. When the Company's proceeds are at a loss, dividends shall not be distributed.</p> <p>Dividends shall be divided equally according to the number of shares, except in the case where the Company issues preferred shares and requires that preferred shares receive dividends different from ordinary shares. To allocate dividends as specified. The dividend payment must be approved by the shareholders' meeting.</p> <p>The interim dividend may be paid from time to time when the Company has reasonable profits to do so and shall report it to the next shareholders' meeting.</p> <p>"Payment of dividends must be made within one (1) month from the date of the shareholders' meeting or the resolution of the Board of Directors' meeting, as the</p>

Existing Articles of Association	New Articles of Association
	<p>case may be. In this regard, written notice shall be sent to the shareholders and such dividend payment shall also be advertised in a newspaper for at least three (3) consecutive days <u>or maybe advertised via electronic media in accordance with the rules and procedures prescribed by law.</u></p>
<p>None (The previous version of the company regulations had 56 provisions)</p>	<p><u>"Article 57. In the event that the Company or the Board of Directors is required to submit letters or documents according to the Public Limited Companies Act B.E. 2535 (including any amendments) to directors, shareholders, or creditors of the Company, and such persons have notified their intention or given their consent to receive such letter or document by electronic means, the Company or the Board of Directors may send the letter or document by electronic means in accordance with the rules prescribed by law.</u></p>

The authorization to assign the Company's directors or any person designated by the Board of Directors to take all necessary actions to complete the registration of approved amendments or additions to the Company's Articles of Association, including the power to make amendments or add wording to the amended Articles of Association of the Company in case the Registrar issues an order and/or advice to amend the wording of such documents. Any such amendments must comply with the order of the Public Company Registrar and should not affect the essence of the amendment to the Company's Articles of Association as approved.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Company Secretary proposed to the meeting to consider and approve the amendment to the Company's Articles of Association

Meeting Resolution The meeting considered and agreement the amendment to the Company's Articles of Association with the following votes:

Agree	231,647,365	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.00
Abstain	0	votes	% equivalent to	0.00

Agenda 12: To consider and approve the amendment of the objectives of the Company and the amendment to Article 3 of the Memorandum of Association of the Company

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the amendment of the Company's Memorandum of Association, specifically Clause 3 (Objectives), in order to encompass the current and future business operations of the Company. The proposed amendment will increase the number of items in Clause 3 from 49 to 58, which has the following details:

1. Amendment objective no. 43

From "Operating private hospitals, nursing homes, treating patients and sick individuals requires adequate training and academic education on medicine and sanitation, including running an animal hospital"

To " Operating private hospitals, nursing homes, treating patients and sick individuals requires adequate training and academic education on medicine and sanitation, including running an animal hospital"

2. Amendment and add 9 objectives as follows:

Article 50. Operating private hospitals, nursing homes, treating patients and sick individuals requires adequate training and academic education on medicine and sanitation, including running an animal hospital

Article 51. Operating inspection, testing, and analysis of raw materials and products through a testing lab. The purpose is to ensure the quality assurance of raw materials and products, including the development and validation of test methods business.

Article 52. Operating providing disease analysis services through the use of various medical technologies, such as X-ray machines, ECG machines, ultrasound machines, laboratory examinations, and pathological anatomy business

Article 53. Operating X-ray inspection services, both in-house and on-site business.

Article 54. Operating hearing tests, vision tests, lung capacity tests, and other physical ability tests related to work business.

Article 55. Operating employee health check-up services for companies and general industrial plants, including pre-employment health check-ups, regular health check-ups during employment, and health check-ups upon leaving the job business.

Article 56. Operating medical laboratory examinations for individuals who will be traveling to work abroad business.

Article 57. Operating organizing a hospital to provide health rehabilitation services for elderly individuals, as well as a nursery for pre-school children business.

Article 58. Operating a radio station focused on health education and public awareness business.

Additional Amendment of the Company's Clause 3 (Objectives) to the Company's Memorandum of Association

"Clause 3. The Company's Objectives comprise 58 clauses as appeared in the enclosed Form Bor Mor Jor. 002"

The authorization to The Board of Directors or a person assigned by the Board of Directors to have the authority to undertake any necessary actions for the registration of the amendment/ addition of the objectives and the Memorandum of Association of the Company as approved until completion, as well as, to amend and add additional wording to the revised version of the Company's objectives and the Memorandum of Association for the case that the public limited company registrar has an order and/or advice to amend such wording in the said documents, in order to comply with those orders without significantly affecting the amendment of the Company's objectives and Memorandum of Association as approved.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Company Secretary proposed to the meeting to consider and approve the amendment of the objectives of the Company and the amendment to Article 3 of the Memorandum of Association of the Company

Meeting Resolution The meeting considered and agreement the amendment of the objectives of the Company and the amendment to Article 3 of the Memorandum of Association with the following votes:

Agree	231,647,365	votes	% equivalent to	100.00
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 13 To consider any other matters (if any)

-None-

The Chairman gave the shareholders an opportunity to ask questions and express their additional opinions.

1. Ms. Usanee Thamtrakuldee, a shareholder, inquired about the Net Profit Margin target for the year 2023 and the strategies to achieve this goal?

Chief Executive Officer answered the question that the Company's recent acquisitions, stating that, through the acquisition of various businesses, the net profit target for the short term is approximately 10% of the total financial budget. For example, if the revenue for this year is 1.8 billion baht, the net profit after tax is estimated to be around 180 million baht. This profit comes from the combined operations of the existing businesses the company has, including the growing new ventures. In addition, the company has informed the media and analysts that it is preparing to register the business of Drug Care Co., Ltd. and Nakhon Patana Co., Ltd. on the MAI. The Company has medium and long-term goals, aiming for a net profit margin of approximately 14-16%. The company believes this is achievable because the hospital business, with its strong brand and highly skilled staff, can generate a net profit margin of up to 20%. Moreover, if the Company can transform its pharmacy business into a digital pharmacy with technology integration such as AI, as seen in various international pharmacy chains, it can achieve a net profit margin of at least 12% or more.

2. Mr. Sakol Sukhawanitwichai, delegated by the Thai Investor Association, inquired about the following: (1) Progress on improving the safety and quality control to meet European standards at Teva's manufacturing facility in Ayutthaya and Modern Pharma in Samut Prakan. (2) Whether the Company has opportunities to enhance relationships with partners to enter international markets. (3) The Company's policies and plans for managing the risk of pandemic diseases to minimize the impact on operations in the animal health product category?

Chief Executive Officer answered the questions as follows:

(1) The Company has plans to upgrade the manufacturing facilities in Ayutthaya to comply with EU standards. Regarding the production of drying agents, there is a signed contract with consultants for Technology Transfer in the production of new drying agents. This is expected to be completed within the next 2 years. As for the Modern Pharma facility, it already complies with PIC/S and GMP PIC/S standards. Upgrading to these standards requires significant investment. Therefore, the company is currently focusing on upgrading only the Ayutthaya facility to enable global distribution of the drying agents.

(2) The Company aims to become an international company as reflected in its name. After the Covid era ends, the Company plans to export products, recently, it has been launched to open the market in United States of America ("USA") and Quick Wins will open the dog and cat food market with 2-3 orders already received. Even dog and cat food must be registered with the United States Department of Livestock Development before it can be purchased. Requesting permission for cosmetics or producing health products for people and animals will take longer to obtain permission. In August, the Company plans to showcase health products for humans and pets at an exhibition in the Middle East, and there are considerations for participating in European exhibitions next year. The Company is also seeking partners to avoid booth exhibitions. Currently,

there is one foreign sales representative responsible for international coordination. At the same time, the company has products for people and pets registered in Vietnam and the market in China has been opened through a platform called Cross-Border, JD Mall, and Export products of Modern Pharma factories to Myanmar, Hong Kong and Cambodia, one of the Company's visions is to bring products to international markets. It will start with dog and cat food products first. As for human cosmeceuticals, toothpaste, herbs, and medicine, it takes quite a long time.

(3) The occurrence of epidemics, such as when there is an epidemic in pigs, causing the pig population to decrease, resulting in decreased purchases. As a result, all companies that are in the business of distributing medical supplies for livestock will be affected or even other entrepreneurs affected by the epidemic have suffered losses. The company plans to diversify into other areas, doing business in this area will be quite volatile. Therefore making many the business has diversified risk into other areas of business.

3. Mr. Apichat Preetimakorn, a shareholder, inquired about the target number of Lab Pharmacy branches to be opened in the year 2023?

Chief Executive Officer answered the question that the target for opening Lab Pharmacy branches in the current year is a total of 15 branches, by the end of the year, there will be a total of 35 branches. The branches that have already opened this year include the one at Future Park Rangsit, and there are plans to open a branch at Don Mueang Airport. The Company has secured additional locations for branches at Siam Paragon and Velocity Sports Club. Furthermore, there are plans to open 4 more branches in Phuket province. The branches in Phuket and Don Mueang Airport are currently in the process of being expedited. Despite challenges, the pharmacy business continues to experience steady growth.

4. Mr. Apichat Preetimakorn and Mr. Chatree Tangseranee inquired about the collaboration and investment with PTT through INNOBIC, they would like to know what businesses there are currently and what types of products?

Chief Executive Officer answered the question that in the past year, there has been an important change in the company, namely the change to Innobic LL Holding Company Limited, which is 100% owned by PTT Public Company Limited ("PTT") to hold 20% of the Company's shares. There was a joint press conference on 7 projects, and the project that happened quickly was that Innobic (Asia) Company Limited ("Innobic Asia") hired the Company to produce dietary supplements and vitamins. which has developed a formula together and production of various dietary supplements must be registered, the Company expects that everything will be completed within the first quarter. But due to some obstacles causing delays, the contract production will be completed in the second quarter and the company expects to have income from Innobic Asia's contract production from the second quarter onwards. As for other projects, such as expanding the pharmacy It may be an expansion of drugstores with other companies in the PTT group, such as PTT Oil and Retail Business Public Company Limited ("OR"), where the company has reserved space in gas stations that are similar About 2-3 Flag Ship branches are a collaboration between the company and OR, and the company will have a joint project with Lotus Pharmaceutical, which Lotus Pharmaceutical Came to visit the factory in Ayutthaya Province.

and assess readiness This may be an option for Lotus Pharmaceutical. It will be used as a production base for medicines or various innovations.

No shareholders made any suggestions or additional questions. The Chairman thanked all shareholders for taking time to attend the meeting and when there was no other business matter, the Chairman adjourned the meeting at 16.35 hrs.

-Signature-

(Clinical Professor Emeritus Dr. Udom Kachintorn)

Chairman of the Board of Directors

-Signature-

(Ms. Chompunuch Meevang)

Company Secretary